Incidence of gastrointestinal side effects due to alendronate is high in clinical practiceBMJ 1997; 315 doi: https://doi.org/10.1136/bmj.315.7117.1235a (Published 08 November 1997) Cite this as: BMJ 1997;315:1235
- Rosemary Kelly, Specialist registrara,
- H Taggart, Consultant physiciana
- a Department of Health Care for the Elderly, Belfast City Hospital, Belfast BT9 7AB
Editor—Recent advertisements in the BMJ for alendronate sodium (Fosamax), which is used in osteoporosis, have stated that “side effects, which usually were mild, generally did not require discontinuation of therapy.” The overall incidence of upper gastrointestinal side effects in clinical trials is given as 1%. Our experience of alendronate in clinical practice is different.
We have studied 77 consecutive women (mean age 65 (range 27-83)) who were treated with alendronate …